Characteristics of Patients With Inflammatory Bowel Disease Who Develop Bloodstream Infection

被引:1
|
作者
Kamada, Mitsuhiro [1 ]
Miyazaki, Motoyasu [1 ]
Nakashima, Akio [1 ]
Yamada, Yota [1 ]
Nakano, Takafumi [2 ]
Hagiwara, Daiki [2 ]
Komiya, Yukie [3 ]
Matsuo, Koichi [1 ]
Imakyure, Osamu [1 ]
机构
[1] Fukuoka Univ, Dept Pharm, Chikushi Hosp, Fukuoka 8188502, Japan
[2] Fukuoka Univ Hosp, Dept Pharm, Fukuoka 8140180, Japan
[3] Fukuoka Univ, Chikushi Hosp, Dept Clin Lab, Fukuoka 8188502, Japan
来源
关键词
Crohn's disease; Ulcerative colitis; Bloodstream infection; PSEUDOMONAS-AERUGINOSA; DIVERSITY;
D O I
10.14740/jocmr4920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The causative microorganisms of bloodstream infec-tions (BSIs) in patients with inflammatory bowel disease (IBD) and the clinical characteristics of these patients have not yet been fully identified. Therefore, this study investigated IBD patients who devel-oped BSI to determine their clinical characteristics and identify the BSI-causing bacteria. Methods: The subjects were IBD patients who developed bactere-mia between 2015 and 2019 at Fukuoka University Chikushi Hos-pital. The patients were divided into two groups according to IBD type (Crohn's disease (CD) or ulcerative colitis (UC)). The medical records of the patients were reviewed to determine their clinical back-grounds and identify the BSI-causing bacteria. Results: In total 95 patients, 68 CD and 27 UC patients were included in this study. The detection rates of Pseudomonas aeruginosa (P. aer-uginosa) and Klebsiella pneumoniae (K. pneumoniae) were higher in the UC group than in the CD group (18.5% vs. 2.9%, P = 0.021; 11.1% vs. 0%, P = 0.019, respectively). Immunosuppressive drugs use was higher in the CD group than in the UC group (57.4% vs. 11.1%, P = 0.00003). Hospital stay length was longer in the UC group than in the CD group (15 vs. 9 days; P = 0.045). Conclusions: The causative bacteria of BSI and clinical backgrounds differed between patients with CD and UC. This study showed that P. aeruginosa and K. pneumoniae had higher abundance in UC patients at the onset of BSI. Furthermore, long-term hospitalized patients with UC required antimicrobial therapy against P. aeruginosa and K. pneumoniae.
引用
收藏
页码:262 / 267
页数:6
相关论文
共 50 条
  • [41] Prostate MRI characteristics in patients with inflammatory bowel disease
    Takahashi, Hiroaki
    Froemming, Adam T.
    Bruining, David H.
    Karnes, R. Jeffrey
    Jimenez, Rafael E.
    Takahashi, Naoki
    EUROPEAN JOURNAL OF RADIOLOGY, 2021, 135
  • [42] Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection
    Bartoletti, Michele
    Vandi, Giacomo
    Furii, Francesca
    Bertuzzo, Valentina
    Ambretti, Simone
    Tedeschi, Sara
    Pascale, Renato
    Cristini, Francesco
    Campoli, Caterina
    Morelli, Maria Cristina
    Cescon, Matteo
    Pinna, Antonio Daniele
    Viale, Pierluigi
    Giannella, Maddalena
    TRANSPLANT INFECTIOUS DISEASE, 2018, 20 (05)
  • [43] Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis
    Ono, Keisuke
    Kishimoto, Mitsumasa
    Deshpande, Gautam A.
    Fukui, Sho
    Kawaai, Satoshi
    Sawada, Haruki
    Matsuura, Minoru
    Rodriguez, Valeria Rios
    Proft, Fabian
    Tada, Kurisu
    Tamura, Naoto
    Taniguchi, Yoshinori
    Hirata, Ayako
    Kameda, Hideto
    Tsuji, Shigeyoshi
    Kaneko, Yuko
    Dobashi, Hiroaki
    Okano, Tadashi
    Haji, Yoichiro
    Morita, Akimichi
    Okada, Masato
    Komagata, Yoshinori
    Medina, Clementina Lopez
    Molto, Anna
    Dougados, Maxime
    Hisamatsu, Tadakazu
    Tomita, Tetsuya
    Kaname, Shinya
    RHEUMATOLOGY INTERNATIONAL, 2022, 42 (10) : 1751 - 1766
  • [44] Clinicopathologic characteristics of clinically relevant cytomegalovirus infection in inflammatory bowel disease
    Akifumi Kuwabara
    Haruhiko Okamoto
    Takeyasu Suda
    Yoichi Ajioka
    Katsuyoshi Hatakeyama
    Journal of Gastroenterology, 2007, 42 : 823 - 829
  • [45] Clinicopathologic characteristics of clinically relevant cytomegalovirus infection in inflammatory bowel disease
    Kuwabara, Akifumi
    Okamoto, Haruhiko
    Suda, Takeyasu
    Ajioka, Yoichi
    Hatakeyama, Katsuyoshi
    JOURNAL OF GASTROENTEROLOGY, 2007, 42 (10) : 823 - 829
  • [46] Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis
    Keisuke Ono
    Mitsumasa Kishimoto
    Gautam A. Deshpande
    Sho Fukui
    Satoshi Kawaai
    Haruki Sawada
    Minoru Matsuura
    Valeria Rios Rodriguez
    Fabian Proft
    Kurisu Tada
    Naoto Tamura
    Yoshinori Taniguchi
    Ayako Hirata
    Hideto Kameda
    Shigeyoshi Tsuji
    Yuko Kaneko
    Hiroaki Dobashi
    Tadashi Okano
    Yoichiro Haji
    Akimichi Morita
    Masato Okada
    Yoshinori Komagata
    Clementina López Medina
    Anna Molto
    Maxime Dougados
    Tadakazu Hisamatsu
    Tetsuya Tomita
    Shinya Kaname
    Rheumatology International, 2022, 42 : 1751 - 1766
  • [47] Latent and Active Tuberculosis Infection in Patients with Inflammatory Bowel Disease
    Jin, Byung Chul
    Moon, Hee Jin
    Kim, Sang Wook
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2022, 80 (02): : 72 - 76
  • [48] Risk of Clostridioides difficile infection in patients with inflammatory bowel disease
    Martinez Lozano, H.
    Saralegui Gonzalez, P.
    Fueyo Pelaez, P. R.
    Garcia Garcia, A.
    Miranda-Bautista, J.
    Reigadas Ramirez, E.
    Alcala Hernandez, L.
    Munoz Garcia, P.
    Marin-Jimenez, I.
    Menchen, L.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I2044 - I2044
  • [49] Risks of Infection among the Older Inflammatory Bowel Disease Patients
    Christina Y. Ha
    Current Treatment Options in Gastroenterology, 2014, 12 (3) : 283 - 291
  • [50] Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease
    Hindryckx, Pieter
    Novak, Gregor
    Bonovas, Stefanos
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (04) : 633 - 641